Description from the EGA: " This is a prospective, single arm phase IIa trial in which patients with early breast cancer will receive pre-operatively two doses of denosumab 120mg subcutaneously one week apart (maximum 12 days) followed by surgery. Tumor, normal breast tissue and blood samples will be collected at baseline and at surgery. Post-operative treatment will be at the discretion of the investigator.Primary...

Summary from the GEO: "In order to investigate the mechanisms underlying defective alveologenesis caused by RANK over-expression in mice, global gene expression profiles from primary acinar cultures of mammary epithelial cells were analyzed." Overall design from the GEO: " Mammary epithelial cells from gestation day 16.5 WT and MMTV-RANK females were obtained. Cultures were established in the presence...